October 12^th at 15:15
Hybrid event
Medisiina D  lecture hall Lauren 1 / Zoom

Prof. Simon L. Goodman, Science and Technology Program Manager, the Antibody Society, Germany
Integrins as drug targets

Professor Goodman will be holding his lecture about the topic of integrins as drug targets on-site in the Medisiina D lecture hall Lauren 1. If you wish to come on-site please  register latest Sunday October 10th
https://link.webropol.com/s/VP-Simon-Goodman

You can also follow the talk online via Zoom, where no registration is required:
https://utu.zoom.us/j/61710469294

Welcome everyone!

Simon L. Goodman is Science and Technology Program Manager for the Antibody Society. He gained his D.Phil in membrane biochemistry from the University of Sussex. His start-up biotechnology company works on antibody validation.  He spent many years at Merck inventing and developing peptide and antibody therapeutics targeting cell adhesion through phase 3 clinical trials in oncology. Prior to Merck, he did post-doctoral work at Max-Planck Society on cellular receptors for laminin, with Klaus von der Mark at Martinsried, Munich and Erlangen, and phenotypic antibody screens with Walter Birchmeier at MPI Tübingen. His work includes the first high resolution X-ray structures of integrins, in collaboration with Dr. Amin Arnaout (Harvard Medical School).  His career in academia and industry has resulted in over 100 peer-reviewed publications, reviews and in many patents.